CB Therapeutics Inc., a Carlsbad, CA-based synthetic biology company focused on the development and biosynthetic production of existing and novel tryptamines and cannabinoids, closed a Series A funding round of undisclosed amount.
The round was filled entirely by re.Mind Capital, a fund launched by Christian Angermayer within Apeiron, his family office.
The company intends to use the funds to accelerate their scaled up manufacturing and sale of cannabinoids and tryptamines.
Led by Sher Ali Butt, CEO, and Dr. Jacob Vogan, CSO, CB Therapeutics is a biotechnology company that develops synthetic biology solutions to address mental health issues and increase healthspan. Its proprietary cellular agriculture platform enables next generation biosynthetic production of cannabinoids and psychedelic medicines and their analogs to further clinical research for various serious health conditions.
In addition to the closing of its Series A, CB Therapeutics added Christian Angermeyer to the Advisor role, along with three new members to its board of directors, which now consists of Dr. Srinivas Rao, CSO of Atai Life Sciences; Dr. Jeff Miller, CEO of Invivoscribe; Jan Hardorp, Founding Partner at re.Mind Capital; and the founders of CB Therapeutics, Sher Ali Butt, CEO, and Dr. Jacob Vogan, CSO.